Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibudilast - MediciNova

Drug Profile

Ibudilast - MediciNova

Alternative Names: AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos

Latest Information Update: 22 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Banyu; Kyorin Pharmaceutical; MediciNova; National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Senju Pharmaceutical; University of California at Los Angeles; University of Colorado at Boulder; University of New South Wales; University of Sydney
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antiallergics; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antiplatelets; Drug withdrawal therapies; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists; Macrophage migration inhibitory factor inhibitors; Nitric oxide synthase inhibitors; Phosphodiesterase 10A inhibitors; Phosphodiesterase 11A inhibitors; Toll-like receptor 4 antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Amyotrophic lateral sclerosis; Globoid cell leukodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alcoholism; Neurological disorders; Opioid abuse; Substance-related disorders

Highest Development Phases

  • Marketed Allergic conjunctivitis; Asthma; Cerebrovascular disorders
  • Phase III Spinal cord disorders
  • Phase II Alcoholism; Amyotrophic lateral sclerosis; Multiple sclerosis; Opioid abuse; Substance-related disorders
  • Phase I/II Chemotherapy-induced damage; Glioblastoma
  • Suspended Neuropathic pain
  • No development reported Brain injuries; Globoid cell leukodystrophy; Headache
  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 28 Oct 2019 MediciNova receives patent allowance for ibudilast in Canada
  • 28 Aug 2019 MediciNova plans a phase IIb/III trial for Amyotrophic lateral sclerosis in USA in October 2019 (PO, Capsule) (NCT04057898)
  • 09 Aug 2019 Ibudilast - MediciNova receives Fast Track designation for Substance-related disorders (methamphetamine dependence) [PO] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top